Recent Finacing
Recent Raise
TILT Biotherapeutics is a clinical-stage biotech developing TILT oncolytic 5/3 adenoviruses armed with TNF‑alpha and IL‑2 (lead TILT‑123) to modulate tumor microenvironment and enable T‑cell and checkpoint inhibitor combinations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
